An ongoing clinical trial supported by a full service global CRO that requires additional monitoring support to successfully meet timelines.
A global, clinical-stage, specialty pharmaceutical company.
Fast-paced, time-sensitive Phase 3 trial, comprised of subjects at high risk of recurrent renal cell carcinoma (RCC) involving 28 US-based sites.
Integration of third-party CRO (ProTrials) for additional monitoring/site payment support
ProTrials developed and implemented a detailed CRO integration plan, which included: